Semaglutide Powder Cas No.910463-68-2

Semaglutide Powder Cas No.910463-68-2

Product Name: Semaglutide Powder
CAS No.:910463-68-2
Product origin: Usually produced by recombinant DNA technology
Content specification: ≥98% (HPLC)
Detection method: RP-HPLC
Active ingredient: Semaglutide
Product fineness: 100-200 mesh
Product properties: White to off-white powder
Product packaging: 5mg, 10mg, 15mg, 20mg, 30mg
Product storage: Protected from light, dry, cool place, relative humidity ≤60%
Shelf life: 24 months
Send Inquiry
Pharmaceutical-Grade Semaglutide Peptide API Powder CAS 910463-68-2

Semaglutide Peptide API | CAS 910463-68-2 | ≥ 98.0% RP-HPLC

✔ GMP-Compliant Facility ✔ Third-Party Tested ✔ Ready for R&D

Xi'an Tihealth Biotechnology Co., Ltd. is a verified global B2B supplier of premium active pharmaceutical ingredients. Semaglutide (Molecular Formula: C187H291N45O59) is a highly potent, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike endogenous GLP-1 which possesses a transient half-life, our API features a sophisticated structural acylation: the attachment of a C-18 fatty diacid side chain via a hydrophilic spacer at position 26. This precise modification dramatically enhances albumin binding affinity, effectively shielding the peptide sequence from Dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage.

Our Semaglutide API is engineered utilizing a hybrid bioprocessing methodology that integrates recombinant DNA fermentation with highly controlled Solid-Phase Peptide Synthesis (SPPS). Purified via orthogonal preparative Reverse-Phase Chromatography (RP-HPLC), our lyophilized powder achieves an exceptional analytical profile, boasting a peptide purity of ≥ 98.0% with strictly controlled TFA (Trifluoroacetic acid) and endotoxin limits.

⚠ REGULATORY COMPLIANCE, RUO & BOLAR EXEMPTION NOTICE

  • Research Use Only (RUO): This lyophilized Semaglutide is an unformulated raw API. It is strictly dispensed for laboratory research, analytical profiling, and authorized pre-clinical trials. It is NOT a sterile finished drug for direct human or veterinary injection.
  • Patent Disclaimer (Bolar Exemption): Products currently protected by valid patents are not offered for commercial sale in jurisdictions where such sale constitutes patent infringement. This API is supplied strictly under the Bolar Exemption provision exclusively for R&D, analytical testing, and regulatory submission purposes.

Technical Data Sheet (TDS) & Analytical Specifications

Analytical Parameter Xi'an Tihealth Specification Test Methodology
Product Identity Semaglutide Mass Spectrometry (MS)
CAS Number 910463-68-2 Chemical Registry
Chromatographic Purity ≥ 98.0% RP-HPLC (UV 214nm/254nm)
Peptide Content (N%) ≥ 80.0% (Dry basis) Elemental Analysis
TFA (Trifluoroacetic Acid) ≤ 1.0% (Strictly Controlled) Ion Chromatography (IC)
Appearance White to off-white lyophilized powder Visual Inspection
Bacterial Endotoxins < 5.0 EU/mg LAL Kinetic Chromogenic

Evidence-Based Pharmacological Mechanisms

01

Glucose-Dependent Insulin Secretion

Binds to pancreatic beta cells, triggering a robust, glucose-dependent release of insulin to minimize hypoglycemia risks.

02

Hepatic Glucagon Suppression

Suppresses inappropriate glucagon secretion, reducing hepatic glucose output to correct fasting hyperglycemia.

03

Satiety Modulation

Slows gastric transit and interacts with hypothalamic centers to suppress appetite signaling for weight management efficacy.

Formulation & Laboratory FAQ

01. How does the structural acylation of Semaglutide alter its pharmacokinetics?

The C-18 fatty diacid side chain binds to serum albumin, shielding the peptide from enzymatic degradation and renal filtration, yielding a half-life of ~165 hours.

02. What is the difference between "Peptide Purity" and "Peptide Content"?

Purity (≥ 98.0%) indicates the percentage of target sequence vs. impurities. Content (≥ 80.0%) reflects the actual peptide mass in the powder, accounting for counter-ions and moisture.

03. Does this API include the SNAC absorption enhancer?

No, this is the unformulated pure peptide base API. Formulators must independently compound the peptide with SNAC for oral dosage forms.

Ready to Accelerate Your Peptide R&D?

Contact Sales Team Now

Hot Tags: Semaglutide Powder Cas No.910463-68-2, China Semaglutide Powder Cas No.910463-68-2 manufacturers, suppliers, factory, tranexamic powder

Send Inquiry